| | Business Summary | | Pharmacopeia,
Inc.
designs,
develops,
markets
and
supports
science
and
technology-based
products
and
services
intended
to
improve
and
accelerate
the
processes
of
drug
discovery
and
chemical
development.
The
Company's
Software
Segment
provides
molecular
modeling
and
simulation,
bioinformatics
and
cheminformatics
software
that
facilitates
the
discovery
and
development
of
new
drug
and
chemical
products
and
processes
in
the
pharmaceutical,
biotechnology,
chemical,
petrochemical
and
materials
industries.
The
Company's
Drug
Discovery
Services
Segment
provides
drug
discovery
services
to
pharmaceutical
and
biotechnology
companies
based
on
proprietary
combinatorial
chemistry
and
high
throughput
screening
technologies. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Pharmacopeia,
Inc.
develops
combinatorial
chemical
libraries
and
uses
these
libraries
alone,
and
through
collaborations,
to
discover
new,
low
molecular
weight
compounds
for
use
as
pharmaceuticals.
For
the
six
months
ended
6/30/01,
revenues
rose
9%
to
$56.3
million.
Net
loss
totaled
$11.2
million,
up
from
$2.7
million.
Revenues
reflect
higher
software
license
sales
due
to
acquisitions.
Net
income
was
offset
by
higher
S/G/A
expenses
due
to
the
acquisitions. | | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| Joseph Mollica, Ph.D., 59
Chairman,
Pres, CEO | $660K | Stephen Spearman, Ph.D., 50
Exec.
VP and COO for Pharmacopeia's Drug Discovery business | 334K | Michael Stapleton, Ph.D.
Exec.
VP and COO for Pharmacopeia's Software business | -- | Bruce Myers, 44
Sr.
VP and CFO | 338K | Thomas Carney
Sr.
VP and Gen. Counsel | -- | | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/p/pcop.gif)